Read more from the company presentation here.
-----
And as I mentioned previously, NMTC has 5 must-see potential catalysts right now:
No. 1 NMTC Potential Catalyst - A Low Float Provides Volatility Potential Daily
According to the Yahoo Finance website, NMTC has a low float.
The website reports this profile to have approximately 13.71Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could positive 2023 company news help provide a near term spark?
-----
No. 2 NMTC Potential Catalyst - Bullish Technical Indicators Are Appearing Across The Short, Medium, And Long Term
I'm telling you right now... Don't discount NMTC's technical indicators.
At 11:00AM EST Monday, NMTC was displaying several triggered technical indicators across the short, medium term, and long term.
Barchart was reporting these technical indicators as triggered:
Short Term Indicators
- 20 - 50 Day MACD Oscillator
- 20 - 100 Day MACD Oscillator
- 20 - 200 Day MACD Oscillator
Medium Term Indicators
- 50 Day Moving Average
- 50 - 150 Day MACD Oscillator
- 50 - 200 Day MACD Oscillator
Long Term Indicators
- 100 Day Moving Average
- 150 Day Moving Average
- 200 Day Moving Average
- 100 - 200 Day MACD Oscillator
The website also shares its all-important "Trend Seeker" composite indicator is triggered, too.
Could this be a signal that NMTC could be gearing up for a special move ahead?
-----
No. 3 NMTC Potential Catalyst - Business Update + Upcoming Targeted Milestones
NeuroOne® Reports First Quarter Fiscal Year 2023 Fi-nan-cial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., Feb. 14, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal first quarter 2023 ended December 31, 2022.
Fiscal First Quarter 2023 and Recent Business Updates
- Received FDA 510(k) clearance to market the Evo® sEEG Electrode technology for temporary (less than 30 day) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, enabling NeuroOne to fully address the approximately $100M diagnostic electrode market.
- A feasibility animal study of the Company's OneRF® therapeutic radiofrequency ablation electrode system was completed under the guidance of Dr. Jamie Van Gompel at the Mayo Clinic in Rochester, MN. OneRF is an sEEG probe-guided RF based system to monitor and adjust settings based on temperature throughout an ablation, a feature designed to improve the safety of the procedure.
- The first commercial order of Evo® sEEG electrodes for temporary use (less than 30 days) was shipped to the Company's distribution and development partner Zimmer Biomet. NeuroOne continues to build up inventory to meet product forecasts and fulfill additional orders in-house.
- The Company developed and successfully bench tested an early prototype of a first-of-a-kind device that can deliver drugs (or other diagnostic or therapeutic agents) to the brain while also having the capability to stimulate and record before and after application.
- Held discussions with strategic organizations regarding the Company's technology in an effort to potentially expand the product footprint in neurology.
- Exhibited the Evo electrode product family with Zimmer Biomet at the Congress of Neurological Surgeons annual meeting and the American Epilepsy Society and Congress of Neurological Surgeons annual meetings.
...
- CEO Dave Rosa featured on Fox Business Network's 'Mornings with Maria.'
- Rang Nasdaq St-ock Market closing bell to commemorate the FDA clearance milestone for Evo sEEG Electrode technology.
Dave Rosa, CEO of NeuroOne, commented, "We were thrilled to receive FDA clearance of our Evo sEEG electrode, which was the culmination of years of hard work and determination. This represents the beginning of our commercialization strategy with Zimmer Biomet. Just as critical, we are well positioned to submit our OneRF Ablation System to the FDA for 510(k) clearance, marking a key milestone for the Company as we enter the therapeutic space. We continue to explore additional exciting markets as we seek to improve upon existing technology with the goal of making current procedures safer and more cost effective, with potential improved efficacy for patients suffering from epilepsy, Parkinson's disease, and chronic pain. We also continue to explore potential strategic partnerships to expand our presence beyond our current areas of focus."
Upcoming Targeted Milestones
- Commercial launch of Evo sEEG electrodes with Zimmer Biomet in the first quarter of calendar year 2023.
- Along with Zimmer Biomet, present the newly launched Evo sEEG system at the American Association of Neurological Surgeons (AANS) annual meeting at the end of April 2023.
- Submit a 510(k) application to the FDA for OneRF in the second quarter of calendar year 2023.
- Complete design verification testing for OneRF confirming that the full feature system meets its design specifications and is fully functional.
- Complete next in vivo animal testing of the OneRF system with multiple surgeons with the objective of gathering additional in vivo data on the system's performance.
- Pre-clinical implantation for spinal cord stimulation (SCS) electrodes intended for permanent implant to treat chronic pain.
...
Read the full article here.
-----
No. 4 NMTC Potential Catalyst - Shipping/Order Of Evo sEEG System Seen As A "Monumental Achievement"
NeuroOne® Ships Initial Zimmer Biomet Order for its Evo® sEEG System for Less than 30 Day Use
Company focused on manufacturing and commercialization in partnership with Zimmer Biomet
EDEN PRAIRIE, Minn., Nov. 30, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it shipped the first commercial order to Zimmer Biomet for its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. Zimmer Biomet is the exclusive worldwide distribution partner for the NeuroOne Evo Cortical and sEEG electrode product lines.
"This shipment represents a monumental accomplishment for the Company. Without the persistence of our staff and manufacturing partners, we could not have reached this point. We look forward to commercialization of this exciting technology in the future in partnership with Zimmer Biomet," said Dave Rosa, CEO of NeuroOne.
The Evo sEEG System represents the Company's second FDA 510(k) cleared product. NeuroOne now provides a full line of electrode technology to address an estimated worldwide market of $100Mn for patients requiring diagnostic brain mapping procedures. As opposed to cortical electrodes, sEEG electrodes provide a similar function at the subsurface level of the brain by using a much less invasive process that does not require removal of the top portion of the patient's skull. sEEG electrodes are the predominant technology used in these procedures due to their less invasive placement and subsurface location.
...
As previously reported, NeuroOne is also advancing a pipeline of therapeutic electrode technologies for brain tissue ablation and chronic stimulation use for DBS (deep brain stimulation) and spinal cord stimulation for chronic back pain. These therapeutic electrode technologies represent addressable markets valued between $500Mn and $6Bn.
Read the full article here.
-----
No. 5 NMTC Potential Catalyst - FDA 510(k) Clearance Is Most Exciting And Important Accomplishment To Date
NeuroOne® Receives FDA 510(k) Clearance to Market its Evo® sEEG System for Less than 30 Day Use
Company focused on manufacturing ramp for commercialization in partnership with Zimmer Biomet
EDEN PRAIRIE, Minn., Oct. 25, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.
...
"I am extremely proud of the entire NeuroOne team and their relentless pursuit of this clearance. Despite the challenges we faced, our team remained focused and persistent in driving this successful conclusion. This is clearly our most exciting and important accomplishment to date. We are now able to advance our commercialization efforts in partnership with Zimmer Biomet, our distribution and development partner. We look forward to continuing to execute our strategic plan, which next up includes our RF ablation system, the Company's first therapeutic electrode technology," said Dave Rosa, CEO of NeuroOne.
The Evo sEEG System represents the Company's second FDA 510(k) cleared product. NeuroOne now provides a full line of electrode technology to address an estimated worldwide market of $100Mn for patients requiring diagnostic brain mapping procedures. As opposed to cortical electrodes, sEEG electrodes provide a similar function at the subsurface level of the brain by using a much less invasive process that does not require removal of the top portion of the patient's skull. sEEG electrodes are the predominant technology used in these procedures due to their less invasive placement and subsurface location.
The Company's Evo Cortical and sEEG Electrodes are a portfolio of hi-definition thin film electrodes. Potential advantages include increased signal clarity and reduced noise; better tactile feedback during insertion into brain tissue; and faster order fulfillment due to an automated manufacturing process.
As previously reported, NeuroOne is also advancing a pipeline of therapeutic electrode technologies for brain tissue ablation and chronic stimulation use for DBS (deep brain stimulation) and spinal cord stimulation for chronic back pain. These therapeutic electrode technologies represent addressable markets valued between $500Mn and $6Bn.
Read the full article here.
-----
NMTC Recap: 5 Potential Breakout Catalysts To Know Immediately
No. 1 - A Low Float Provides Volatility Potential Daily
No. 2 - Bullish Technical Indicators Are Appearing Across The Short, Medium, And Long Term
No. 3 - Business Update + Upcoming Targeted Milestones
No. 4 - Shipping/Order Of Evo sEEG System Seen As A "Monumental Achievement"
No. 5 - FDA 510(k) Clearance Is Most Exciting And Important Accomplishment To Date
-----
Coverage is officially reinitiated on NMTC. When time permits, do this:
